Tissue-type plasminogen activator and anisoylated plasminogen streptokinase activator complex reduced the odds of early death in acute myocardial infarction by 29% and 46%, respectively.
Meta-Analysis
Do tissue-type plasminogen activator and anisoylated plasminogen streptokinase activator complex reduce early death in patients with acute myocardial infarction?
Both tissue-type plasminogen activator and anisoylated plasminogen streptokinase activator complex significantly reduce early mortality in acute myocardial infarction.
Effect estimate: OR 0.71 and OR 0.54
An overview of eight randomized controlled trials of tissue-type plasminogen activator (Alteplase or Duteplase) and 10 of anisoylated plasminogen streptokinase activator complex (Anistreplase) showed that the odds of early death were reduced by 29% by tissue-type plasminogen activator and 46% by anisoylated plasminogen streptokinase activator complex, with overlapping 95% confidence intervals. Although the beneficial effects of both agents are consistent and are strengthened when all the trials are considered together, the available data do not permit comparisons of the relative efficacy of these two agents with each other or with streptokinase.
Held et al. (Thu,) conducted a meta-analysis in acute myocardial infarction. tissue-type plasminogen activator and anisoylated plasminogen streptokinase activator complex vs. control was evaluated on early death (OR 0.71 and OR 0.54). Tissue-type plasminogen activator and anisoylated plasminogen streptokinase activator complex reduced the odds of early death in acute myocardial infarction by 29% and 46%, respectively.